Research & Education

2015/2016 - Optimal Utilization of Anti-Angiogenesis Therapy for NSCLC

June 23, 2016 at 7:00PM Central European Summer Time - Recording Available

 

 

 

Federico Cappuzzo, MD

Martin Reck, MD PhD
Department of Thoracic Oncology
German Center for Lung Research
Lungen Clinic Grosshansdorf

Name of Reviewer(s): 

              

Laurie Gaspar, MD, PhD- Advisory Board/Honoraria: Astrazeneca.

Name of Planner(s): 

 

Pia Hirsch-Nothing to Disclose      Carlos Ferreira-Nothing to Disclose

 

Name of Activity: 

 

ASLC European Webinar Series - 2015/2016 - Optimal Utilization of Anti-Angiogenesis Therapy for NSCLC

Date of Activity:

 

06/23/2015

Faculty/Speaker(s) Disclosures:

COI Resolution:Ensure a balanced discussion of alternative. Do not use trade names. Do not refer to company names or logos. Do not recommend therapies.

“All planning committee members’, reviewers, planners and faculty et al. identified conflicts of interest pertaining to this activity were resolved prior to the activity.”

 

  • SpeakerMartin Reck, MD PhD
  • Speakers' Bureau
  • Speakers or Advisory Board
  • Honoraria

From: Hoffmann-La Roche, Lilly, BMS, MSD, AstraZeneca, Boehringer-Ingelheim, Pfizer, Novartis, Celgene.

 

Type of Activity: 

 Live Course

  Internet Live Course (Webinar)XXXX

 Internet Enduring Material

Are there Commercial Supporters for this activity?

      No

If yes, please list:

Country of Origin: Germany

This presentation will provide an overview of the concept of angiogenesis and antiangiogenesis in NSCLC as one of the "hallmarks of cancer".  Available data with bevacizumab - containing regimens in patients with advanced non squamous NSCLC - will be briefly reviewed.  Clinical trial results with new antiangiogenic compounds like the anti-VEGFR2 antibody ramucirumab and the angiokinase inhibitor nintedanib will be shown.  These studies demonstrated superior efficacy for combination  therapy with docetaxel compared to docetaxel alone in patients with pretreated NSCLC.  

Tolerability, patient reported outcomes, and potential clinical biomarkers will also be addressed.  An outline of potential future strategies to utilize antiangiogenic compounds will be outlined.  Potential treatment approaches in patients with activating EGFR mutations, where the combination of bevacizumab and erlotinib have shown interesting results will also be described.  Last, the rationale for combining antiangiogenic compounds and immunotherapies will be examined.

Following the didactic presentation Dr. Reck will address questions from the audience. There will be ample opportunity for discussion and comments. Attendees may submit questions and comments to the faculty via internet chat. This CME live webinar series is designed to meet the educational needs of healthcare professionals who diagnose and treat patients with lung cancer, including medical oncologists, thoracic surgeons, pulmonologists, radiation oncologists, radiologists, pathologists and advanced practice nurses and physicians' assistants.

At the conclusion of this webinar learners will be able to:

  • Describe an overview of the concept of angiogenesis and antiangiogenesis in NSCLC as one of the "hallmarks of cancer".
  • Demonstrate superior efficacy for combination  therapy with docetaxel compared to docetaxel alone in patients with pretreated NSCLC.
  • Analyze Potential treatment approaches in patients with activating EGFR mutations, where the combination of bevacizumab and erlotinib

Please complete the evaluation link provided to you after the activity. The Certificate of credit will be ready for you to print or save for your records.

Registration is on a first-come, first-served basis. Participation is limited.

DOWNLOAD RECORDING

IASLC Guidelines For Individuals Planning and/or Presenting a IASLC CME Activity

IASLC Financial/Commercial Relationships and Conflicts of Interest Policy

IASLC Honoraria Policy

IASLC Commercial Support Agreement (LOA)

CME INFORMATION:

Financial/Commercial Relationships & Conflicts of Interest DISCLOSURES

All individuals able to influence or control content of any CME certified activity that will be presented were required to complete a Financial Relationships/Conflicts of Interest Disclosure Form prior to the Internet Live Course.

“A Conflict of Interest (COI) is created and exists when individuals in a position to control the content of CME, or their spouses/partners, that have a relevant personal financial relationship within the past 12 months with a commercial interest that produces, markets, re-sells, or distributes health care goods or services consumed by, or used on, patients that benefits the individual in any financial amount, and therefore may bias their opinions and teachings. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or any other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research and clinical trials), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities for which remuneration is received or expected.”

This IASLC CME educational activity was planned and developed to: uphold academic standards to ensure balance, independence, objectivity, and scientific rigor; adhere to requirements to protect health information under the Health Insurance Portability and Accountability Act of 1996 (HIPAA); and, include a mechanism to inform learners when unapproved or unlabeled uses of therapeutic products or agents are discussed or referenced.

IASLC CME assures that the planners/reviewers/authors/faculty/peer reviewers et. al. conflicts of interest were identified, reviewed and resolved from all individuals involved in the development or able to influence and control the content of this CME activity. IASLC CME assures that disclosure is given prior to an educational activity being delivered to learners. Any individual who failed or refused to disclose relevant financial relationships was disqualified from this CME activity and removed from future IASLC CME activity presentations. All commercial relationships and conflicts of interest identified were thoroughly vetted by IASLC Ethics Committee, CME Subcommittee, and/or an independent reviewer. COI was evaluated by the Board of Directors of the IASLC for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. IASLC CME is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial entity.

The above Financial Disclosures are from the speakers, moderators, reviewers, and planning committee members (et al.) their spouse/life partner have disclosed regarding financial interest/arrangement or affiliation with any commercial interests that produce, market, re-sell, or distribute healthcare goods or services for patients that are relevant to this presentation(s) or that have provided commercial support for this continuing medical education activity.

CREDIT STATEMENT:

IASLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

IASLC CME designates this Internet Live Course activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

GOAL & PURPOSE:

This presentation will provide an overview of the concept of angiogenesis and antiangiogenesis in NSCLC as one of the "hallmarks of cancer".  Available data with bevacizumab - containing regimens in patients with advanced non squamous NSCLC - will be briefly reviewed.  Clinical trial results with new antiangiogenic compounds like the anti-VEGFR2 antibody ramucirumab and the angiokinase inhibitor nintedanib will be shown.  These studies demonstrated superior efficacy for combination  therapy with docetaxel compared to docetaxel alone in patients with pretreated NSCLC.  

TARGET AUDIENCE:

This CME live webinar was designed to meet the educational needs of healthcare professionals who diagnose and treat patients with lung cancer, including medical oncologists, thoracic surgeons, pulmonologists, radiation oncologists, radiologists, pathologists and advanced practice nurses and physician assistants.

LEARNING OBJECTIVES:

After attending this session, participants will:

    • Describe an overview of the concept of angiogenesis and antiangiogenesis in NSCLC as one of the "hallmarks of cancer".
    • Demonstrate superior efficacy for combination  therapy with docetaxel compared to docetaxel alone in patients with pretreated NSCLC.
    • Analyze Potential treatment approaches in patients with activating EGFR mutations, where the combination of bevacizumab and erlotinib

DISCLAIMER:

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The content has been reviewed for conformity with ACCME Essentials, Policies, and Standards for Commercial Support.

TO RECEIVE CME CREDIT:

Upon completion of the electronic evaluation link the CME Certificate will be ready for you to print or save for your records. This information is used not only to evaluate the present activity, but also to plan for future programs.

If you are interested in obtaining the CME Credits for these sessions you must indicate this when you register for the program.  CME credit is only given for the Internet Live Course.

 

Location Local time Time zone UTC offset
New York (U.S.A. - New York) Thursday, June 23, 2016 at 1:00:00 PM EDT UTC-4 hours
Amsterdam (Netherlands) Thursday, June 23, 2016 at 7:00:00 PM  CEST UTC+2 hours
Paris (France) Thursday, June 23, 2016 at 7:00:00 PM CEST UTC+2 hours 
London (United Kingdom) Thursday, June 23, 2016 at 6:00:00 PM BST UTC+1 hours
Brussels (Belgium) Thursday, June 23, 2016 at 7:00:00 PM BST UTC+2 hours
Barcelona (Spain) Thursday, June 23, 2016 at 7:00:00 PM CEST UTC+2 hours
Belfast (United Kingdom - Northern Ireland) Thursday, June 23, 2016 at 6:00:00 PM BST UTC+1 hours
Berlin (Germany) Thursday, June 23, 2016 at 7:00:00 PM CEST UTC+2 hours
Dublin (Ireland) Thursday, June 23, 2016 at 6:00:00 PM IST UTC+1 hours
Moscow (Russia) Thursday, June 23, 2016 at 8:00:00 PM MSK UTC+3 hours
Prague (Czech Republic) Thursday, June 23, 2016 at 7:00:00 PM CEST UTC+2 hours
Glasgow (Scotland) Thursday, June 23, 2016 at 6:00:00 PM CEST UTC+1 hours
Corresponding UTC (GMT) Thursday, June 23, 2016 at 17:00:00    

How to use the Time Zone Converter